CRISPR Therapeutics and ViaCyte have formed a strategic collaboration to develop gene-edited, stem cell-derived therapies for diabetes patients.
ViaCyte will receive $15m and an additional $10m through a convertible promissory note from CRISPR Therapeutics, post the execution of the agreement.
Based in Switzerland, CRISPR Therapeutics is a developer of transformative gene-based medicines for patients suffering from life-threatening diseases, while ViaCyte is a US-based developer of regenerative medicines used for treating diabetes.
The partnership will enable CRISPR Therapeutics to strengthen its presence in the regenerative medicines sector.
Integral Molecular and Merus N.V. have collaborated for the development of various undisclosed targets.
The strategic collaboration will utilise Integral Molecular’s proprietary technology, MPS Discovery Engine®, to develop a range of innovative therapeutic monoclonal antibodies. The technology enables the isolation of monoclonal antibodies targeting complex membrane proteins.
Based in the US, Integral Molecular is a biotechnology company engaged in the development of drugs for the treatment of cancer, HIV and arthritis, while Merus is a Netherlands-based clinical-stage immuno-oncology company that develops bispecific antibody therapeutics.
The partnership will enable Merus to advance its pipeline into pre-clinical and clinical studies.
Evotec has signed a research collaboration agreement with Almirall to develop novel therapeutics in the field of dermatology.
Almirall will pay research funding to Evotec, in addition to milestone-based payments and other royalties, as part of the agreement.
The alliance combines Evotec’s advanced drug discovery and development platforms with Almirall’s dermatology disease expertise in psoriasis and atopic dermatitis.
Based in Germany, Evotec is a drug discovery and development company, while Almirall is a Spanish pharmaceutical company engaged in the discovery and development of medicines for dermatological diseases.
The collaboration is expected to focus on highly validated targets through an innovative approach to deliver superior drug products.
Cancer Genetics and NovellusDx have signed a definitive merger agreement, as part of which the latter will merge with a newly formed subsidiary of the former based in Israel.
NovellusDx’s shareholders will receive stock equal to 49% of the equity in Cancer Genetics, as part of the agreement.
Based in the US, Cancer Genetics is a developer of molecular and biomarker-based tests in the field of oncology, while NovellusDx is an Israel-based developer of tumour specific driver mutations used for treating cancer.
The merger will combine Cancer Genetics’ data set related to tumour biology with NovellusDx’s proprietary technology and strengthen the former’s therapeutic development and improve treatment success rates.
Raymond James has been appointed as financial adviser to Cancer Genetics, while Chardan is acting as financial adviser to NovellusDx for the transaction.